MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

R&D project on psilocybin’s benefits in treating diseases of the brain

VANCOUVER, BCNov. 30, 2021 /CNW/ – MYND Life Sciences Inc.  (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin on treating diseases of the brain.

MYND Life Sciences will benefit from advisory services and up to $45,600 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a prescribed research and development project that will run from November 2021 to March 2022.

“We are very pleased for the support from the Government of Canada, both from the business advisory perspective, as well as the valued funding support,” said Dr. Lyle Oberg, MD, CEO, MYND Life Sciences. “We are taking a broad-based, measured approach to harness private capital  investment, invaluable university research infrastructure, and guidance backed with funding from important government research enablers to tackle some of the most serious diseases of the brain and central nervous system.”

The project is titled Phytochemical-analog(s) as a novel method for management of treatment resistant depression. The objective of the research and development is to determine how psilocybin analogs target a particular gene pathway to modulate brain function.

“This support through NRC IRAP is well timed and will enable an important piece of our overall approach to creating novel innovations to improve the lives of people suffering from diseases of the Central Nervous System,” stated Dr. Wilfred Jefferies, Chief Science Officer, MYND Life Sciences.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.

Win + Support + Microdose + Covid-19 🍄: issue 25

Here’s what’s in store for you in today’s issue:

🍄 Results from a global microdosing study

🍄  Ayahuasca vs. placebo

🍄 3D-printed psychedelics

🍄 Can mushrooms fight covid?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Where Religion And Psychedelics Collide

In this episode of the Daily Mushroom Podcast, we have Peg Peters. Peg is setting up a ketamine-assisted psychotherapy clinic just outside of Vancouver, BC. He discovered psychedelics in his mid 40s, taking a 6g dose of psilocybin mushrooms while accompanied by a therapist. After that experience his career in psychedelics took off!

Therapeutic banner

Ayahuasca vs placebo

An ayahuasca retreat could make you more empathetic!

In a recent study, participants reported reduced stress, anxiety, and depression after attending an ayahuasca ceremony… even those who were given a placebo. 

However, only the ayahuasca users showed increased empathy.

The supportive group atmosphere could explain why people experienced benefits even without taking ayahuasca. 

Don’t get triggered

Researchers discovered that DOI (a psychedelic that’s similar to LSD and mescaline) can reduce anxiety and increase neural plasticity. Rats stopped showing anxious behaviours in response to fear triggers after a single dose!

How psychedelic ceremonies change your beliefs

A survey of ~900 psychedelic ceremony attendees revealed that psychedelic use is associated with a decreased belief in materialism, an increase in transcendentalism, and improved mental health. Participants showed more moderate views on metaphysical beliefs after the ceremony rather than extreme stances.

inspirational banner

GIVEAWAY ALERT 🚨

You could win $4,000+ in prizes for supporting legal access to psychedelics!

By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.

If that’s not enough, you’ll also be entered to win an incredible prize package including:

  • A scholarship towards a Holos Plant Medicine retreat (Value: $1,500)
  • A 2-night stay at the Sentinel Retreat Centre (Value: $500)
  • A functional mushroom wellness package from Eversio Wellness (Value: $300)
  • 1 of 3 Physiology of Trauma premium masterclass packages from Nectara (Value: $900)
  • And more!

Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.

Purchase a membership before December 10th to be entered in the giveaway!

Get ready for a psychedelic TV series coming this summer!

This month’s issue of Los Angeles Magazine features an in-depth cover story on the city’s recent obsession with psychedelics. 

Now, the story is being developed into a drama/comedy series called Psychedelic City (think Silicon Valley meets Limitless).

The writer hopes the show will “wipe away some of the stigmas that have been attached to psychedelics.”

The developers are also creating a Psychedelic City metaverse platform with immersive art, music, and experimental therapies. 

business banner

Biomind Labs (BMND) developed a new way to manufacture psychedelics using 3D printers and lasers. By printing the formulation layer by layer, the company can control exactly when the drug is released and adjust doses for each patient.

LOVE Pharma (LUV) signed a letter of intent to acquire Microdoz Therapy Inc. to accelerate a psilocybin trial for cannabis use disorder. Seems ironic considering that the company also sells THC and CBD oral strips!

Entheon Biomedical (ENBI) has begun testing the stability of its DMT formulation in preparation for a study on nicotine addiction.

PharmaTher (PHRM) applied for an orphan drug designation for a ketamine treatment for a rare seizure condition called Status Epilepticus. If approved, the designation would give the company potential tax credits, grant eligibility, and exclusive marketing rights.

Pasithea Therapeutics (KTTA) began offering an esketamine nasal spray at its UK clinics. It’s one of just three clinics in the UK that have been approved to provide the treatment.

MYND Life Sciences (MYND) began research on its biomarker test that aids in diagnosing multiple sclerosis. There are currently no physical indicators or lab tests that can diagnose the condition.

Researchers are turning to fungi to treat covid!

In an upcoming clinical trial, agarikon and turkey tail mushrooms will be given to covid-positive patients with mild symptoms. Researchers hope that the mushrooms’ antiviral and immune-boosting properties will prevent symptoms from worsening.

In a separate trial, the same blend of mushrooms will be given to subjects while getting vaccinated to see if it can boost antibody levels.

Industry Quick Hits

Nov 22 – Emyria Ltd (EMD) receives $5 million from one of Australia’s largest private investment groups Read more…

Nov 23 – Cybin (CYBN) Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities Read more…

Nov 23 – COMPASS Pathways (CMPS) granted fifth US patent for crystalline psilocybin Read more…

Nov 24 – Seelos Therapeutics (SEEL) Acquires Exclusive License of iX Biopharma’s Proprietary Wafer-Based Ketamine Delivery Platform Read more…

Nov 24 – NeonMind (NEON) Announces Successful Completion Of Pre-IND Consultation With FDA On Clinical Path For Obesity Drug Candidate NEO-001  Read more…

Nov 26 – Numinus (NUMI) Receives Conditional Approval to Graduate to the Toronto Stock Exchange Read more…

Video of the Week

Playlist of the Week

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics

VANCOUVER, BCNov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing procedure for diagnosing and monitoring Alzheimer’s Disease (“AD“) utilizing the Company’s proprietary anti-inflammatory peptide (“MAP“) biomarker.

“Our research team has begun to research and explore the potential application of our proprietary MAP biomarker for use in the identification of Alzheimers disease”, stated Dr. Lyle Oberg, CEO of MYND. “The ability to make an early, accurate, dependable diagnosis in Alzheimer’s Disease patients thereby allowing for earlier intervention is a huge step forward in the fight against this terrible disease. We are extremely excited that the MAP biomarker has the potential to bridge that gap. The Company’s ultimate goal specific to diagnostics is to provide a cost-effective, easy to use diagnostic test kit that can be administered from anywhere with a dried blood spot. Helping families and health care practitioners with an effective tool for early diagnosis, monitoring and treatment for the millions impacted by this disease will be a significant innovation in central nervous system medicine”.

MYND Diagnostics will be initiating a clinical validation of the MAP biomarker in AD by collecting known blood samples of AD and quantifying the presence of MAP against control samples. This validation is planned to start in first quarter 2022.  Pending those results, the Company anticipates that a submission for FDA approval could take place as early as second half 2022 to prepare for commercialization and making the MAP Biomarker available to the public through healthcare practitioners. The Company’s goal is to develop diagnostic test to monitor and potentially diagnose inflammatory diseases of the central nervous system such as Alzheimer’s Disease. The Company’s diagnostic test is intended to give health care providers an objective monitoring tool to improve patient outcomes by providing more tailored and efficacious treatments.

Approximately 44 million people worldwide live with AD or a related form of dementia.1  It is the sixth-leading cause of death in the U.S., killing more people than breast cancer and prostate cancer combined.2 Only approximately one in four people with the disease get diagnosed.3 Further, the Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6.6 billion in 2020, and it is expected to reach approximately USD 9 billion in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.4

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc., the parent company of MYND Diagnostics Inc., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION

MYND Life Sciences Inc.
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.

1. https://alzheimersnewstoday.com/alzheimers-disease-statistics/
2. https://alzheimersnewstoday.com/alzheimers-disease-statistics/
3. https://alzheimersnewstoday.com/alzheimers-disease-statistics/
4. https://www.researchandmarkets.com/reports/4591925/alzheimers-disease-diagnostics-and- therapeutics utm_source=BW&utm_medium=PressRelease&utm_code=stxjrv&utm_campaign=1533504+-+Alzheimer%27s+Disease+Diagnostics+and+Therapeutics+Market+-+Global+Growth%2c+Trends%2c+COVID-19+Impact%2c+and+Forecasts+2021-2026%3a+Focus+on+Cholinesterase+Inhibitors+%26+NMDA+Receptor+Antagonists&utm_exec=chdo54prd

Smoke weed with a veteran on DMT: issue 23

Here’s what’s in store for you in today’s issue:

🍄 How weed influences your trip

🍄 Healing veterans with DMT

🍄 The results from the biggest psilocybin study ever!

🍄 At-home ketamine therapy

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Functional Mushrooms for Health & Nutrition with FreshCap CEO Tony Shields

In the episode of the Daily Mushroom Podcast, we have Tony Shields, CEO of FreshCap. Tony’s knowledge on mushrooms is deep and expansive and stems from a childhood fascination with these magnificent fungi. If you want to learn more about the benefits of functional mushrooms, this podcast is for you.

Therapeutic banner

The results from the world’s biggest psilocybin trial are in!

COMPASS Pathways’ (CMPS) stock dropped nearly 30% after announcing mixed study findings and Q3 financial results on Monday.

The company conducted a trial on 233 patients to determine the best psilocybin dose for treatment-resistant depression (TRD).

All three groups showed improvements the day after receiving the dose. The group with the largest dose had the best results, with 36.7% of patients showing at least a 50% decrease in depression scores and 29.1% in remission at week 3. A quarter of the patients showed sustained improvements until week 12.

Unfortunately, 12 patients experienced serious adverse events such as suicidal ideation or self harm, but these behaviours are common in patients with TRD.

The company is preparing for a larger trial beginning next year.

COMPASS also announced that it lost $15.8 million or $0.38 per share in Q3, an improvement compared to its $1.30 loss per share in Q3 of last year.

Here’s a graph that shows the impact on levels of depression reported by trial patients: 👇🏽

Why ketamine is so effective at preventing suicide

Researchers have known for years that ketamine can reduce depression symptoms and suicidal ideation in as little as 24 hours, but a recent study helps us understand why it’s so beneficial.

The study showed that a single dose of ketamine rapidly improved cognitive function, problem-solving abilities, and distorted thinking in suicidal patients.

“Being able to think more clearly can make someone feel less suicidal,” explains Ravi. N. Shah, MD, one of the researchers.

Ketamine was more effective than Midazolam, a benzodiazepine used as a sedative for surgeries. After the dose, suicidal ideation was diminished for up to 6 weeks.

Treating alcoholism and depression with half the dose

Cybin (CYBN) announced that its psilocybin formulation for depression and alcoholism, CYB003, could be more effective than oral psilocybin.

The company conducted preclinical testing on multiple species of animals. Researchers found that CYB003 has nearly double the brain penetration compared to oral psilocybin, resulting in a 50% reduction in dosage, variability, and onset time.

A smaller dosage has potential to reduce negative side effects such as nausea. The formulation could lead to shorter sessions which would make treatment more affordable!

inspirational banner

Can weed make your trip better?

A bit of weed could make your trip more spiritual and less scary.

A survey of 321 people suggests that using cannabis while on psychedelics increases the odds of mystical experiences, ego deaths, and intense visuals. 

The data also showed that low doses of cannabis reduced the chances of bad trip, whereas high doses increased feelings of fear and insanity.

Healing veterans with DMT

In honour of Veteran’s Day, we’re sharing how a Special Ops veteran cured his chronic pain and PTSD with DMT.

Asher Gibson was diagnosed with PTSD and traumatic brain injury after countless combats across the world. Prescription medications began to dominate his life, so he turned to psychedelic healing.

After smoking DMT, the powerful compound found in ayahuasca, Asher was blasted out of his body and traveled through different dimensions to the beginning of time.

“I remember my whole head being ecstatic and numb, like the most wonderful electrical massage on my brain. The feeling moved down my neck and shoulders and eventually filled my entire body.”

After the trip, Asher’s debilitating neck and shoulder pain was almost non-existent and his mental state subsided to manageable levels. He is no longer dependent on prescription drugs.

“While DMT isn’t the magic button that fixes everything, I believe it’s a powerful guide to help you do the work yourself,” he explains.

To bring this kind of relief to other veterans, consider supporting the Heroic Hearts Project – a non-profit organization that provides ayahuasca retreats for veterans with combat experience or military sexual trauma.

Insurance coverage for ketamine therapy

A major hurdle of making psychedelic therapy accessible to all will be getting the treatment covered by insurance.

That’s why we’re excited to share that Novamind (NM) has secured coverage for ketamine treatments from four major health insurance providers: Blue Cross Blue Shield, the University of Utah, PEHP Health & Benefits and MBA Benefit Administrators!

The company’s Chief Medical Officer says that this a promising signal that insurance providers are interested in more effective mental health treatments as research emerges.

Novamind has also opened a call center dedicated to insurance verification to ensure that patients are approved and reimbursed as quickly as possible.

business banner

Congrats to the top psychedelic companies of 2021!

These leading psychedelic companies were recognized for their accomplishments at Microdose Psychedelic Insights’ Wonderland: Miami – the world’s largest psychedelic business event, ever.

Company of the Year: Cybin Inc. (CYBN)

Psilocybin Company of the Year: MycroDose Therapeutics (private)

Ketamine Company of the Year: Field Trip Health (FTRP)

Ibogaine Company of the Year: MindMed (MNMD)

DMT Company of the Year: Psilera Bioscience (private)

LSD Company of the Year: MindMed (MNMD)

MDMA Company of the Year: MAPS (non-profit)

Platform Company of the Year: MindMed (MNMD)

Drug Development Company of the Year: Awakn Life Sciences (AWKN)

Retreat of the Year: Synthesis

Clinic of the Year: Awakn Life Sciences (AWKN)

B2C Tech Company of the Year: Fireside Project (non-profit)

B2B Tech Company of the Year: MycroDose Therapeutics (private)

Try psychedelic therapy at home in these states

TripSitter Clinic Corp. now offers at-home ketamine therapy in 10 states! 

The company, which is part of Origin Therapeutics’ portfolio, expanded its services to eight new states: Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia, in addition to California and Illinois.

Patients can receive a prescription for oral ketamine after a virtual consultation with a physician. They then take the medication at home with virtual guidance, followed by therapy sessions.

This is a promising step toward greater ketamine accessibility. 💪🏼

legal banner

Psilocybin production increases 11,900% in 2021

To keep up with the growing demand for psychedelic research, the DEA is yet again increasing the legal production quotas for certain Schedule I substances.

The original proposal for psilocybin was just 50 grams, which increased to 1,500 grams in September. The final quota is now 6,000 grams – a total increase of 11,900%!

Production of both MDMA and DMT increased 6,300% from 50 grams to 3,200 grams.

Industry Quick Hits

Nov 5 – Fluence Raises $1.6M for Psychedelic Therapy Training Read more…

Nov 5 – MAPS and Momentum Events Announce Collaboration on Psychedelic Science 2023 Read more…

Nov 8 – Blackhawk Growth’s (BLR) MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clinical Trials Read more…

Nov 8 – Delic Corp (DELC) Acquisition Of Ketamine Wellness Centers Is Complete Read more…

Nov 8 – NeonMind (NEON) And SRx Health Solutions Announce Strategic Alliance To Establish Specialty Mental Health Clinics For Interventional Psychiatry Treatments Read more…

Nov 9 – MYND Life Sciences (MYND) Executes LOI to Enter into a Clinical Research Collaboration with Revitalist Read more…

Nov 9 – Nova Mentis (NOVA) Files Genetic Neuroinflammatory Disease Patent Read more…

Nov 9 – Herbal Supplement Giant, Irwin Naturals (IWINF), To Enter THC & Psychedelics Industries Read more…

Nov 11 – PharmaTher (PHRM) Announces Positive Research Results for Psilocybin Microneedle Patch Read more…

Video of the Week

Playlist of the Week

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation

VANCOUVER, BCNov. 9, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has executed a binding letter of intent (“LOI“) with REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist“) (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics’ proprietary anti-inflammatory peptide (“MAP“) biomarker. The MAP diagnostic is intended to give health care providers an objective monitoring tool to detect and diagnose mental illness more accurately than the current diagnostic methodology, which can be very subjective. If successful, this biomarker test has the potential to lead to earlier diagnosis of mental illness and ongoing treatment decisions with the goal of improving patient outcomes by providing more tailored and efficacious treatments.

The goal of the collaboration with Revitalist is to utilize their broad network of clinics with patients suffering from mental illness to commence clinical trials to demonstrate MAP’s ability to diagnose and monitor mental health in order to gain approval by the U.S. Food and Drug Administration (“FDA“). The parties anticipate that initial clinical trial will be focused on patients with mental health issues who had previously been infected with COVID-19 and are seeking medical help for post COVID-19 mental health symptoms (“Brain Fog“). The World Health Organization reports that COVID-19 has affected more than 249 million individuals1. Research indicates that approximately 50% on average of those with COVID-19 have reported having lasting effects2. Revitalist has a network of over 2,300 patients through its multiple clinics in the United States, with many of those patients having been previously infected with COVID-19 and seeking specialized treatments to deal with Brain Fog and other lasting effects.

Dr. Lyle Oberg, MD, CEO of MYND stated “A critical step in diagnostics development is demonstrating that an investigational tool produces consistent results. With the new collaboration we intend to design next phase clinical validation studies and take blood samples from existing patients at Revitalist with an expectation that we will submit the MYND biomarker (MAP) data to the FDA for approval in Q2 of 2022. The Company anticipates generating near-term revenue through research and development projects related to MAP. Ultimately, MYND intends to work with physicians to adopt MAP in their practices and provide access to patients and insurance providers for reimbursement when utilizing our proprietary diagnostic. We anticipate that working with Revitalist will be our first of many mental health studies. Their comprehensive network of patients and expert providers will provide the MYND Diagnostics team with optimal research conditions to study MAP in patients so dearly needing better diagnostic and treatment options.”

Kathryn Walker, CEO of Revitalist stated “We are excited to be working with MYND Diagnostics to potentially diagnose and monitor mental health using MAP. Prior to MAP the only diagnostic for mental health was an interview with the patient regarding their history of symptoms, which of course can be very subjective. A diagnostic tool such as MAP would allow for a more objective diagnosis and monitoring, hopefully resulting in a higher level of care and treatments for our patients. One size doesn’t fit all with mental health and treatments that work for some may not work for others. Utilizing MAP would allow us to quickly adjust treatments to better address patient specific mental health issues.”

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc., the parent company of MYND Diagnostics Inc., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT REVITALIST LIFESTYLE AND WELLNESS

Revitalist Lifestyle and Wellness Ltd. is a publicly traded company, headquartered in Knoxville, Tennessee, with five clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.

CONTACT INFORMATION

MYND Life Sciences Inc.
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

https://covid19.who.int
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003773#sec016

SOURCE MYND Life Sciences Inc.

A better way to get drunk: issue 21

Here’s what’s in store for you in today’s issue:

🍄 The future of psychedelics, according to an expert

🍄 A better way to get drunk

🍄 A first-of-its-kind severe anxiety study

🍄 The race for a dementia treatment

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

The DMT Cure to Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

A better way to get drunk

This psychedelic makes you feel drunk. Could it be used to treat alcoholism?

5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.

Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials are expected to begin in the second half of 2022. 

The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.

First-of-its-kind study on severe anxiety

Monash University just got the go-ahead to conduct a first-of-its-kind study!

Yesterday, the Australian university received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).

Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).

The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.

Does neuroplasticity benefit healthy people too?

Psychedelics clearly have a huge impact on people with mental health issues, but how do they impact people who are already mentally healthy? A new research project at University College London will give us more insights!

After two years of planning, the university is launching the “Understanding Neuroplasticity Induced by Tryptamines” or UNITy Project.

UNITy Project will use fMRI scans, eye-tracking, and experience sampling to understand how the naturally functioning brain responds to various tryptamines (psychedelics that bind to serotonin receptors, such as psilocybin).

The first study will evaluate how DMT affects language processing, sensory processing, and memory in both healthy participants and heavy drinkers, and if neuroplasticity drives the results.

inspirational banner

The future of psychedelics, according to this pioneering researcher

Rick Doblin, a pioneering psychedelic researcher and activist, made some interesting predictions about the future of psychedelics in the US:

  • MDMA will be FDA-approved by the end of 2023, with psilocybin following a year or two after.
  • By 2023 or 2024, there will be 6000+ psychedelic therapy clinics (there are currently about 1000). Every town with a hospice center will have enough demand for a psychedelic clinic.
  • By 2030, one million MDMA therapy sessions will have been administered by 25,000 trained therapists.
  • A licensed legalization model could be implemented around 2035 in which patients can earn a license to use psychedelics outside the clinic once undergoing a supervised session.

Doblin is hopeful that the tremendous impacts on mental health will result in a spiritualized society that “has finally come to the point of embracing global thinking, global humanity, and dealt with economic inequity.”

Donation heals traumatized children

“We’re all traumatized children running around in adult bodies, and (psychedelic) medicines can help us all,” according to venture capitalist Sanjay Singhal.

That’s why his charity donated $5 million to launch The Nikean Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN).

The centre will study psilocybin therapy as a treatment for terminally-ill patients, patients with body dysmorphia, families who have lost a child, and grieving caregivers. It will also study 5-MeO-DMT as a PTSD treatment and will train therapists to administer psychedelic therapy.

Singhal, who was diagnosed with bipolar disorder in his 30s, was inspired to fund psychedelic research after a psilocybin trip helped him break down his emotional walls and fix his relationships.

Can shrooms make you a better leader?

Magic mushrooms may have been the key to this NHL legend’s success.

Mark Messier, the only NHL player to lead two different teams to Stanley Cup championships, said that a magic mushroom trip at age 19 sparked his interest in spirituality and the power of the mind.

“I had no idea the mind was that powerful. Obviously it turned out to be an amazing experience, but more important was the question afterwards: wow, how can I use my mind to empower myself to be a better player, to be a better person, to have more energy, to create a better aura?”

The trip inspired Messier to learn about Eastern philosophies, Buddhism, Indigenous spirituality, and meditation, which had a major influence on him both as a player and a leader.

business banner

Tripping on an island to help frontline workers

Cybin (CYBN) is sending therapists on a psychedelic retreat so they can learn how to provide support to frontline healthcare workers.

Clinical trial facilitators will head to a small island in Washington to be trained on Cybin’s new EMBARK therapy model and gain experiential knowledge of psychedelics. The EMBARK model combines aspects of several psychotherapy models and incorporates patients’ spiritual experiences, bodily experiences, and relationships into the healing process.

The retreat will prepare the facilitators for an upcoming clinical trial at the University of Washington that aims to treat healthcare workers suffering from COVID-related distress, depression, anxiety, and PTSD.

Optimizing the DNA of plant medicines 

Delic Labs of Delic Corp (DELC) is partnering with GT Research Inc. to help mushroom and cannabis producers optimize their products. 

Through the deal, Delic Labs will use DNA analysis to evaluate the commercial value of different cannabis and psychedelic mushroom strains based on certain gene traits. The services will help Canadian producers optimize their compounds through genetic engineering to produce more effective plant medicines.

Which company will develop a dementia treatment first?

If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050 — reaching $1.1 trillion in care costs.

Fortunately, two more companies joined the race to develop a new treatment using psychedelics!

On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.

Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.

Researching ADHD treatments in Korea

These companies are joining forces to develop unique treatments for a range of debilitating conditions.

Agtech Global International Inc. (AGGL) and  KRTL Biotech Inc. are partnering to develop CBD and psilocybin-based medicines to treat conditions like ADHD, pain from cancer, autism, PTSD, depression, and addiction.

The agreement will leverage KRTL’s team of researchers in the US and Korea, where they have already received the Korean equivalent of FDA approval to study the compounds.

Several other companies are supporting the research project including Here To Serve Holding Corp. (HTSC) and Pervasip Corp. (PVSP).

legal banner

Here’s what you missed:

  • Next Tuesday, Detroit will vote on a bill to decriminalize possession and therapeutic use of entheogens including psilocybin mushrooms, ayahuasca, and peyote. Read more…
  • A DC non-profit called The Plant Medicine Coalition issued $50K in grants to community organizations that promote psychedelic education and reform thanks to donations from Dr. Bronner’s soap company. Read more…
  • Dr. Bronner’s is also funding a lobbyist group that’s working to legalize psilocybin for therapeutic uses in Connecticut. Read more…

Industry Quick Hits

Oct 25 – HAVN Life (HAVN) Announces Departure Of Rick Brar As Director Read more…

Oct 26 – Nova Mentis (NOVA) Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome Read more…

Oct 27 – Mindset Pharma (MSET) Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Read more…

Oct 27 – PharmaTher (PHRM) Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022 Read more…

Oct 28 – Blackhawk Growth’s (BLR) Subsidiary MindBio Therapeutics Appoints Patrick Moher as Advisor Read more…

Oct 28 – Greenbrook TMS (GTMS) Announces Dates For Its Third Quarter 2021 Financial Results Read more… 

Oct 28 – MYND Life Sciences (MYND) Announces Appointment of New Director Read more…

Oct 29 – Blackhawk Growth (BLR) Files Fiscal Year Ended June 30, 2021 Financial Reports Read more…

Video of the Week

Playlist of the Week

jack O' lantern mushroom

MYND Life Sciences Announces Appointment of New Director

MYND Life Sciences Announces Appointment of New Director

VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) announces the following changes to its Board of Directors.

The Board has accepted the resignation of Aaron Bowden, who has served on the Board since the establishment of the Company. MYND thanks Mr. Bowden for his many contributions and for his service to MYND.

The Board has appointed Scott L. Nicoll to act as a new independent member of the Board. Mr. Nicoll will also serve as the interim Chair of the Audit Committee, replacing Mr. Bowden. Mr. Nicoll is a partner in the law firm of Panorama Legal LLP, in Surrey, BC. He was called to the Bar in British Columbia in 1994 and has always practiced as a civil litigator, primarily in the areas of commercial, indigenous and administrative law. Mr. Nicoll currently serves as board chair of Food Banks BC and Vice-Chair of the Surrey Urban Mission Society (“SUMS”). Food Banks BC is the only provincial umbrella association of food banks in BC, representing more than one-hundred food banks. SUMS is currently the largest operator of shelter beds for the homeless in the Fraser Valley and a key partner of BC Housing in providing shelter relief to the homeless in the South Fraser region. Mr. Nicoll was a member of the Kwantlen Polytechnic University Board of Governors for more than six years, the last two of which as Board Chair. Mr. Nicoll has a particular interest and expertise in board governance, both having advised various boards as legal counsel and having served on three boards for significant periods of time. Mr. Nicoll has extensive training and a significant interest in various board governance models.

The Board believes Mr. Nicoll’s leadership and extensive governance experience will be extremely valuable for the Company.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.

Which company will develop a dementia treatment first?

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050, reaching $1.1 trillion in care costs.

Fortunately, two more companies joined the race to develop a new treatment using psychedelics!

On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.

Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.

PDF of article 1

PDF of article 2

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer’s disease.

VANCOUVER, BC, Oct. 27, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND”) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has entered into an agreement to acquire the right, title and interest in and to the intellectual property rights for the use of psychedelics to treat Dementia (the “Acquired Assets”) from Cava Healthcare Inc. (“Cava”), a life sciences company based in Surrey, British Columbia. The acquisition includes all future worldwide rights relating to the use of psychedelics to treat Alzheimer’s disease and other dementias.

Under the agreement, the consideration to be paid by MYND to Cava for the Acquired Assets shall be 450,000 common shares of the Buyer (“Shares”) at a deemed price of $0.85 per Share and $120,000. In addition, MYND shall pay to Cava an annual royalty equal to the greater of: (i) $240,000; or (ii) 4% of the net sales of any product or service which directly or indirectly incorporates the Acquired Assets to any third party.

The closing of the purchase and sale of the Acquired Assets is conditional upon MYND obtaining conditional approval of Canadian Securities Exchange for the listing of the Shares.

Dementia is a devastating neurodegenerative condition that leads to severe cognitive decay in older populations and worsens with age. The World Health Organization estimates that between 44 and 50 million people worldwide suffer from dementia. The estimated cost of caring for people with dementia, including Alzheimer’s Disease, in the USA alone, was a staggering $305 billion in 2020 (source: Alzheimer’s Association) and is expected to reach $1.1 trillion by 2050. The number of Americans living with Alzheimer’s disease is predicted to nearly triple by 2050 unless improvements in medical care are made. MYND intends to be at the forefront of these advances.

“Dementia, including Alzheimer’s disease, touch almost all families in some way, usually with very dramatic and emotionally painful consequences,” explains Dr. Lyle Oberg, MD, CEO of MYND. “As we continue to draw the enthusiasm of investors, we are able to take tangible steps towards moving beyond preclinical and into clinical work with our research team.”

The acquisition is a key landmark for MYND and it builds upon MYND’s significant experience in the psilocybin-assisted psychotherapy sector, including methods for treatment-resistant depression, under the leadership of Dr. Lyle Oberg, MD, MYND CEO.

Mr. Theo Warkentin, Cava CEO, stated, “MYND is an innovative industry leader in psychedelic psychotherapy, therapeutics and diagnostics. The company is uniquely positioned to pursue the effectiveness of psilocybin and other psychedelics for treating dementias.”

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.